waypoint wealth counsel Makes New Investment in IQVIA Holdings Inc. $IQV

waypoint wealth counsel acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,558 shares of the medical research company’s stock, valued at approximately $246,000.

Several other institutional investors also recently modified their holdings of the business. Clal Insurance Enterprises Holdings Ltd grew its position in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after buying an additional 131 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA in the first quarter valued at approximately $33,000. Trust Co. of Toledo NA OH bought a new stake in IQVIA in the second quarter valued at approximately $39,000. Finally, Larson Financial Group LLC boosted its holdings in IQVIA by 109.9% in the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 144 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

IQVIA Stock Down 2.3%

Shares of NYSE:IQV opened at $198.35 on Friday. The business’s 50 day simple moving average is $189.02 and its two-hundred day simple moving average is $168.19. The firm has a market cap of $33.72 billion, a P/E ratio of 28.70, a PEG ratio of 2.18 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $237.34.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the prior year, the company earned $2.64 earnings per share. The company’s quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on IQV shares. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday. UBS Group upped their price target on shares of IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. Barclays upped their target price on IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday, October 2nd. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Cowen restated a “buy” rating on shares of IQVIA in a research report on Wednesday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $236.45.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.